Clinical Trial: A Study of Efficacy and Safety of FXS6837 in Anti-C5 Treated PNH Patients.

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07914894) titled 'A Study of Efficacy and Safety of FXS6837 in Anti-C5 Treated PNH Patients.' on Oct. 13.

Brief Summary: This is an single arm, open label designed phase III study to evaluate the efficacy and safety of oral FXS6837 capsules in PNH patients with residual anemia despite the stable treatment with anti-C5 antibody.

Study Start Date: Jan. 26, 2027

Study Type: INTERVENTIONAL

Condition: Paroxysmal Nocturnal Hemoglobinuria

Intervention: DRUG: FXS6837 Capsule

FXS6837 capsule will be taken orally for 24 weeks

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Published by HT D...